Cargando…

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

BACKGROUND: Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist for the preventive treatment of migraine. METHODS: In the double-blind, phase 3 ADVANCE trial, participants with 4–14 migraine days/month were randomized to atogepant 10 mg, 30 mg, 60 mg, or placebo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwedt, Todd J, Lipton, Richard B, Ailani, Jessica, Silberstein, Stephen D, Tassorelli, Cristina, Guo, Hua, Lu, Kaifeng, Dabruzzo, Brett, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739573/ https://www.ncbi.nlm.nih.gov/pubmed/34521260 http://dx.doi.org/10.1177/03331024211042385

Ejemplares similares

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
por: Lattanzi, Simona, et al.
Publicado: (2022)

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
por: Goadsby, Peter J, et al.
Publicado: (2019)

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
por: Dodick, David W., et al.
Publicado: (2020)

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
por: Lipton, Richard B., et al.
Publicado: (2022)

Magnetic resonance spectroscopy studies in migraine
por: Nikolova, Simona, et al.
Publicado: (2022)

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
por: Ailani, J., et al.
Publicado: (2019)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Structural alterations of the brainstem in migraine
por: Chong, Catherine D., et al.
Publicado: (2016)

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
por: Ailani, Jessica, et al.
Publicado: (2020)

Correlations between Brain Cortical Thickness and Cutaneous Pain Thresholds Are Atypical in Adults with Migraine
por: Schwedt, Todd J., et al.
Publicado: (2014)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review
por: Ailani, Jessica, et al.
Publicado: (2023)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

The Characteristics of White Matter Hyperintensities in Patients With Migraine
por: Chong, Catherine D., et al.
Publicado: (2022)

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial
por: Yarnitsky, David, et al.
Publicado: (2019)

Temporal Lobe Cortical Thickness Correlations Differentiate the Migraine Brain from the Healthy Brain
por: Schwedt, Todd J., et al.
Publicado: (2015)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
por: Jensen, Rigmor H., et al.
Publicado: (2023)

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

The migraine postdrome: An electronic diary study
por: Giffin, Nicola J., et al.
Publicado: (2016)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hdgbduljqq15dt0au464iscbsc